Loading data for JAZZ — first visit, this takes a few seconds.

알림

Jazz Pharmaceuticals (JAZZ)

NasdaqGS: JAZZ · 실시간 가격 · USD

254.28

+5.58 (2.24%)

종가 기준: Aug 21, 2026, 8:00 PM

263.50

+3.63%

애프터마켓: 7:52 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

2.24% (1D)

데이터 없음

매수호가	250.24
시가총액	16.51B
매출 (ttm)	4.6B
순이익 (ttm)	940.75M
	0.36
	14.61
	17.4
	9.87
P/B (ttm)	3.43
P/S (ttm)	3.59
실적 발표일	Nov 4, 2026

매도호가	273.51
거래량	516,622
평균 거래량 (20일)	825,808
시가	248.75
전일 종가	248.70
일중 범위	248.70 - 255.85
52주 범위	122.50 - 265.05
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

JAZZ 소개

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic l...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Jun 1, 2007

직원 수 2,890

상장 거래소 NasdaqGS

티커 JAZZ

웹사이트 https://www.jazzpharma.com

전체 기업 정보

재무 실적

2025년 Jazz Pharmaceuticals의 매출은 4.27B로, 전년 4.07B 대비 4.88% 증가했습니다. 순이익은 -356.15M로, -163.58% 감소했습니다.

재무제표

어닝 서프라이즈

Jazz Pharmaceuticals가 Aug 3, 2026에 분기 실적을 발표했습니다:

매출 $1.21B 예상치 하회 $0, 및 15.55% 전년 대비 성장.
EPS 5.71 예상치 하회 -0.47, 및 169.21% 전년 대비 성장.

다음 실적 발표

Jazz Pharmaceuticals의 실적 발표 예정일은 Nov 4, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

1주 전 · StockStory

3 Profitable Stocks with Questionable Fundamentals

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my...

2주 전 · TheStreet

Jazz Pharma buys the only shot at a disease with no FDA treatment

Jazz Pharmaceuticals (JAZZ) just made a bet on a disease that many investors have never heard of. On August 10, the drugmaker agreed to buy privately held Actio Biosciences. The prize is an experiment...

2주 전 · StockStory

5 Revealing Analyst Questions From Jazz Pharmaceuticals’s Q2 Earnings Call

Jazz Pharmaceuticals delivered a positive Q2, with a strong 16% year-over-year revenue increase driven primarily by its oncology and rare disease portfolios. Management attributed the quarter’s perfor...

2주 전 · Zacks

Axsome's Q2 Earnings Meet Estimates, Auvelity Drives Y/Y Revenues

AXSM's Q2 earnings meet estimates, but revenues miss forecasts. Auvelity and other product sales drive year-over-year revenues.

2주 전 · MT Newswires

Jazz Pharmaceuticals' Actio Acquisition 'Makes Sense,' Has Good Synergy, RBC Says

Jazz Pharmaceuticals' (JAZZ) recent acquisition of Actio Biosciences' KCNT1 epilepsy asset "makes se

2 페이지 중 1

Jazz Pharmaceuticals (JAZZ)